**Supplementary data table S1:**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Nr** | **Gender** | **Molecular diagnosis** | **Tumor** | **Age at diagnosis (months)** |
| 1 | M | ICR1 GOM | WT | 9 |
| 2 | F | ICR1 GOM | Nephroblastomatosis | 11 |
| 3 | F | ICR1 GOM | Nephroblastomatosis | 14 |
| 4 | F | ICR1 GOM | WT | 19 |
| 5 | F | ICR1 GOM | WT | 24 |
| 6 | F | ICR1 GOM | WT | 24 |
| 7 | F | ICR1 GOM | WT | 24 |
| 8 | M | ICR1 GOM | WT | 24 |
| 9 | M | ICR1 GOM | WT | 30 |
| 10 | M | ICR1 GOM | WT | 39 |
| 11 | M | 11p15 pUPD | Neuroblastoma | 4 |
| WT | 11 |
| 12 | M | 11p15 pUPD | Hepatoblastoma | 4 |
| Nephroblastomatosis | Unprecised |
| 13 | F | 11p15 pUPD | Hepatoblastoma | 6 |
| ALL | 24 |
| 14 | M | 11p15 pUPD | WT | 8 |
| 15 | F | 11p15 pUPD | WT | 9 |
| 16 | F | 11p15 pUPD | ACC | 10 |
| 17 | F | 11p15 pUPD | Rhabdomyosarcoma (orbital) | 16 |
| 18 | M | 11p15 pUPD | WT | 18 |
| 19 | M | 11p15 pUPD | WT | 19 |
| 20 | F | 11p15 pUPD | WT | 21 |
| 21 | M | 11p15pUPD | WT | 36 |
| 22 | F | 11p15 pUPD | ACC | 40 |
| 23 | F | 11p15 pUPD | WT | 144 |
| 24 | F | 11p15 pUPD | WT | Unprecised |
| 25 | M | ICR2 LOM | Neuroblastoma | < 1 |
| 26 | M | ICR2 LOM | Hepatoblastoma | < 1 (autopsy) |
| 27 | F | ICR2 LOM | Hepatoblastoma | 2 |
| 28 | M | ICR2 LOM | Neuroblastoma | 9 |
| 29 | F | ICR2 LOM | Rhabdomyosarcoma (pelvis) | 48 |
| 30 | M | ICR2 LOM | Melanoma | 72 |
| 31 | M | ICR2 LOM | Sarcoma (liver) | 74 |
| 32 | M | ICR2 LOM | Thyroid carcinoma | 75 |
| 33 | M | *CDKN1C* mutation | Neuroblastoma | 6 |
| 34 | M | *CDKN1C* mutation | ALL | 120 |
| 35 | F | *CDKN1C* mutation | Ganglioneuroblastoma | between 24 and 36 |

**Table S1: age at tumor diagnosis of the 35 BWS patients. WT: Wilms tumor, ACC: adrenocortical carcinoma, ALL: acute lymphoid leukemia. Nephroblastomatosis were included in the calculation of the tumor risk when patients underwent chemotherapy.**